Lung Cancer Diagnostic and Screening Market, By Test Type, By Cancer Type, By End User, By Geography

Description

Lung Cancer Diagnostic And Screening Market is estimated to be valued at USD 2,980.8 Mn in 2025 and is expected to reach USD 5,845.8 Mn by 2032, growing at a compound annual growth rate (CAGR) of 10.1% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 2,980.8 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	10.10%	2032 Value Projection:	USD 5,845.8 Mn

Lung cancer begins in the lungs and may spread to lymph nodes or other organs in the body, such as the brain. Cancer from other organs also may spread to the lungs. When cancer cells spread from one organ to another, they are called metastases. Lung cancers usually are grouped into two main types such as small cell and non-small cell. These types of lung cancer grow differently and are treated differently. According American Cancer Society non-small cell lung cancer is more common than small cell lung cancer. Different people have different symptoms for lung cancer. Some people have symptoms related to the lungs. Some people whose lung cancer has spread to other parts of the body (metastasized) have symptoms specific to that part of the body. Lung cancer symptoms may include coughing that gets worse or prolonged coughing, chest pain, shortness of breath, wheezing, coughing of blood, feeling very tired all the time, weight loss with no known cause.

According to the Centers for Disease Control and Prevention, lung cancer is the third most common cancer in the U.S. Most people in the U.S. die from lung cancer than any other type of cancer. For instance, According American Cancer Society, an estimated 154,050 Americans were expected to die from lung cancer in 2018, accounting for approximately 25% of all cancer deaths. Doctors may perform several tests to confirm lung cancer such as biomarker test, imaging test, and biopsy.

Market Dynamics

Regulatory approvals and launches of new screening test are expected to propel growth of the global lung cancer diagnostic and screening market during the forecast period. For instance, in August 2020, the U.S. Food and Drug Administration approved the liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS) technology to identify patients with specific types of mutations of the epidermal growth factor receptor (EGFR) gene in a deadly form of metastatic non-small cell lung cancer (NSCLC).

However, high cost of lung cancer screening test is also expected to limit the market growth. For instance, according to the American Board of International medicine a CT scan costs US$ 300 and more. These test one need to take periodically.

Key features of the study:

This report provides in-depth analysis of the global lung cancer diagnostic and screening market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global lung cancer diagnostic and screening market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Abbott, Illumina, Inc, Thermo Fischer Scientific, QIAGEN, Quest Diagnostics Incorporated, NeoGenomics, NanoString, Myriad Genetics, Inc. F. Hoffmann-La Roche Ltd., Danaher, Agilent Technologies, Inc., AstraZeneca, Sanofi, and Janssen Pharmaceuticals, Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global lung cancer diagnostic and screening market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for lung cancer diagnostic and screening market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

Global Lung Cancer Diagnostic and Screening market, By Test Type:
- Biomarkers Tests
- EGFR Mutation Test
- KRAS Mutation Test
- ALK Test
- HER2 Test
- Others
- Imaging Tests
- Computed Tomography (CT) Scan
- Positron Emission Tomography (PET) Scan
- Chest X-RAY
- Others
- Biopsy
- Needle Biopsy
- Bronchoscopy Biopsy
- Open Biopsy
- Others
Global Lung Cancer Diagnostic and Screening Market, By Cancer Type:
- Non-small cell lung cancer
- Small Cell Lung Cancer
Global Lung Cancer Diagnostic and Screening Market, By End User:
- Hospital Associated Labs
- Independent Diagnostic Laboratories
- Diagnostic Imaging Centers
- Cancer Research Institutes
Global Lung Cancer Diagnostic and Screening Market, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- Abbott
- Illumina, Inc
- Thermo Fischer Scientific
- QIAGEN
- Quest Diagnostics Incorporated
- NeoGenomics
- NanoString
- Myriad Genetics, Inc.
- F.Hoffmann-La Roche Ltd
- Danaher
- Agilent Technologies, Inc.
- AstraZeneca
- Sanofi
- Janssen Pharmaceuticals, Inc.

Product Code: CMI4434

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Test Type
- Market Snippet, By Cancer Type
- Market Snippet, By End User
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Test Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Lung Cancer Diagnostic and Screening Market - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Lung Cancer Diagnostic and Screening Market, By Test Type, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Biomarkers Test
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends
EGFR Mutation Test
KRAS Mutation Test
ALK Test
HER2 Test
Others
Imaging Test
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends
Computed Tomography (CT) scan
Positron Emission Tomography (PET) scan
Chest X-Ray
Others
Biopsy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends

6. Global Lung Cancer Diagnostic and Screening Market, By Cancer Type, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Non-small cell lung cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends
Small Cell Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends

7. Global Lung Cancer Diagnostic and Screening Market, By End User, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Hospital Associated Labs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Independent Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Cancer Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

8. Global Lung Cancer Diagnostic and Screening Market, By Region, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
North America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Test Type, 2020 -2032, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Cancer Type, 2020 -2032, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 -2032, (US$ Mn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Test Type, 2020 -2032, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Cancer Type, 2020 -2032, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 -2032, (US$ Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Test Type, 2020 -2032, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Cancer Type, 2020 -2032, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 -2032, (US$ Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Test Type, 2020 -2032, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Cancer Type, 2020 -2032, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 -2032, (US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Test Type, 2020 -2032, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Cancer Type, 2020 -2032, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 -2032, (US$ Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Test Type, 2020 -2032, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Cancer Type, 2020 -2032, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 -2032, (US$ Mn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Company Profiles
- Abbott
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Amgen Inc.,
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Illumina, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Thermo Fisher Scientific Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Lepu Medical Technology(Beijing)Co.,Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- AstraZeneca
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- F. Hoffmann-La Roche Ltd
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Laboratory Corporation of America Holdings.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Agilent Technologies, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- QIAGEN
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Quest Diagnostics Incorporated.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- NeoGenomics Laboratories.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Myriad Genetics, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- GRAIL, LLC.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- DELFI Diagnostics
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies

10. Section

References
Research Methodology
About us and Sales Contact